What to Expect in 2027?
Novel conjugates are where the next generation of ADC development is being decided. The first bispecific ADC has reached the market, dual-payload and alternative-mechanism programs are entering the clinic, and pharma has backed the space with deals and acquisitions across dual-payload, degrader and novel-payload platforms. Meanwhile, classical Topo1 and MMAE payloads face resistance, narrow therapeutic windows and a crowded field, pushing discovery teams to differentiate.
The 6th Novel Conjugates Summit is the only industry-led meeting built exclusively around this science. It covers the most advanced areas of novel payload and format development: dual-payload ADCs, pathway-directed payloads, degrader and oligonucleotide conjugates, bispecific and biparatopic ADCs, and peptide and fragment-based formats. Sessions focus on the questions that decide whether a program succeeds: payload pairing, PK and ratio control, target and format selection, translational models and the preclinical evidence needed for IND.
With 80+ discovery, bioconjugation and R&D leaders from big pharma, ADC- focused and novel conjugate biotechs, and a single-track agenda with no traditional ADC content, it is the one date in the ADC calendar where every presentation and conversation is about what comes next. New data is arriving faster than any single meeting can cover, which is why being in the room matters.
Across a workshop day and two conference days, you will leave with fresh data, practical frameworks for design and translation, and a network of peers working on the same problems. Download the event guide to see the full programme.
Unmissable Event Highlights
Look Beyond Topo1 & MMAE
Hear how teams are designing and testing pathway-directed and alternative-mechanism payloads, to help you decide which mechanisms are worth pursuing and how to overcome resistance in your own pipeline.
Get the Latest on Dual-Payload ADCs
Explore how teams choose payload pairs and tune ratio, PK and tolerability, to help you balance efficacy against toxicity and protect the therapeutic index as you move your program toward the clinic.
Rethink Targeting with Bispecifics & Smaller Formats
Compare bispecific, biparatopic, peptide and fragment-based approaches on selectivity, tumor penetration and clearance, to help you choose the right format for your target and patient population.
Bring Your Own Challenges
Join workshops on rational design and preclinical signposts, plus an open “Burning Questions Session”, giving you the opportunity to pressure test your ideas, and resolve unanswered questions with peers before they become costly late-stage problems.
Attending Companies Include